How many days can a box of selumetinib be taken according to the standard dosage?

Selumetinib is a targeted drug that requires individualized dose adjustment based on the patient's body surface area ( BSA). It is mainly used to treat patients 2 years old and older with NF1-related plexiform neurofibromas. In actual use, the recommended dose of selumetinib is 25 mg/m², taken twice daily at an interval of approximately 12 hours, and is usually continued until disease progression or the patient cannot tolerate it. This medicine needs to be taken on an empty stomach, that is, no food should be eaten 2 hours before or 1 hour after each dose to ensure the absorption effect of the medicine.

The common specifications of selumetinib currently on the market are: 10mg/tablet or 25mg/tablet, with 60 pills per box. The actual dosage varies greatly depending on the body surface area of u200bu200bdifferent patients. For example, for an adult or adolescent patient with a body surface area of u200bu200b1.70-1.89 m², 45 mg twice daily is recommended, for a total daily dose of 90 mg. If the main dosage is 25 mg/tablet, you need to take 3.6 pills a day, that is, about 7 pills every two days. Based on this dosage, a box of 25 mg*60 pills of selumetinib can be used for approximately 16-17 days. For pediatric patients with a smaller body surface area, such as 1.1-1.29m², the corresponding dose is 60mg per day (30mg*2 times), so a box of 10mg*60 tablets can be used for about 10 days. If the daily dose is lower, for example, patients with BSA between 0.55-0.69m², take 20mg+10mg a day, that is, a total of 30mg, then 10mg*60 tablets can be taken for 20 days.

It can be seen that the number of days of taking a box of selumetinib completely depends on the patient's body surface area and the corresponding dose setting. This drug treatment needs to strictly follow the guidance of professional doctors, and determine the specific dose after calculating the BSA based on the patient's height and weight. In addition, the fine-tuning of the dose needs to be carried out on the basis of adequate monitoring of adverse reactions and efficacy to avoid insufficient doses that affect the efficacy or excessive doses that lead to toxic reactions.

Reference materials:https://www.koselugo.com